AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

TLX · NASDAQ · Biotechnology

Telix Pharmaceuticals

Commercializes prostate-cancer imaging agents while developing radiopharmaceutical diagnostics and treatments.

$11.29

After-hours close+0.02 (+0.18%)

At close$11.27(−0.92%)

Something off on this page? Send us feedback.

Profile

Telix Pharmaceuticals LimitedTLXHealth Care

Illuccix and Gozellix are commercially available gallium PSMA-PET imaging agents for prostate cancer. The platform combines clinical development with manufacturing and U.S. radiopharmacy distribution while pursuing imaging and therapeutic programs in brain, kidney, and prostate cancer.

Illuccix and Gozellix are commercially available gallium PSMA-PET imaging agents for prostate cancer. They anchor a business that develops and commercializes diagnostic and therapeutic radiopharmaceuticals and associated medical technologies for oncology and rare diseases.

The pipeline includes brain- and kidney-cancer imaging programs and therapeutic candidates for brain and prostate cancer. Internal research is paired with clinical assets, manufacturing and distribution sites, and a U.S. radiopharmacy network, creating a vertically integrated delivery platform.

Operations span the United States, United Kingdom, Canada, Brazil, Europe, and Japan. Commercial expansion depends on regulatory authorizations and resubmissions, clinical-trial execution, reimbursement and pricing, raw-material supply, and manufacturing and distribution capability.

Company facts

CEOChristian Behrenbruch

ListedNov 13, 2024

ExchangeNASDAQ

HeadquartersNorth Melbourne, Australia

CountryAustralia

Employees1,149

CIK0002007191

ISINUS87961M1053

Key statistics

Market cap$3.82B

EPS (ttm)$0.0997

P/E (ttm)113.29

ROE7.1%

P/B7.54

P/S4.05

Dividend yield—

Beta1.05vs XLV −0.19

Year to date +47.9% · Average volume (30d) 122.5K

Analysts

Price target, next 12 months$18.00+59.4%Median of 5 analysts · vs the Aug 28 close

ConsensusBuy4 of 5 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $11.29

High$18.00+59.4%

Median$18.00+59.4%

Low$18.00+59.4%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Jul 16, 2026	RBC Capital	Downgrade	Outperform	Sector Perform	$17	$18
Dec 14, 2025	RBC Capital	Target				$17
Sep 23, 2025	UBS	Reiterate		Buy		$20
Sep 10, 2025	H.C. Wainwright	Target				$20
Aug 28, 2025	JP Morgan	Downgrade	Overweight	Neutral

Earnings

EPS

Estimate$0.04

Reported$0.11+140.3%

Revenue

Estimate$479.6M

Reported$477.0M−0.5%

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 19, 2026Q2 FY26	$0.04	$0.11	+140.3%	$479.6M	$477.0M	−0.5%	+2.02%
Feb 19, 2026Q4 FY25	$0.03	−$0.01	−135.4%	$418.5M	$413.4M	−1.2%	+14.61%
Aug 20, 2025Q2 FY25	$0.13	−$0.01	−105.1%	$322.9M	$388.6M	+20.4%	+10.21%
Feb 20, 2025Q4 FY24	$0.09	$0.07	−25.2%	$135.1M	$367.8M	+172.3%	+12.00%

View details

Financial highlights

	Q4 FY23	Q2 FY24	Q4 FY24	Q2 FY25	Q4 FY25	Q2 FY26
Revenue	$201.8M	$135.4M	$425.7M	$424.9M	$444.5M	$495.3M
Gross profit	$160.5M	$88.8M	$276.4M	$206.6M	$234.6M	$255.5M
Operating income	−$11.2M	$9.9M	$49.0M	$11.3M	$7.0M	−$14.3M
Net income	$14.0M	$8.4M	$27.4M	−$2.5M	−$5.2M	$39.8M
Diluted EPS	$0.04	$0.02	$0.08	−$0.01	−$0.02	$0.11
Gross margin	79.5%	65.6%	64.9%	48.6%	52.8%	51.6%
Operating margin	-5.5%	7.3%	11.5%	2.7%	1.6%	-2.9%

Revenue by geography · FY25

United States$562.3M · 99%

China$7.0M · 1%

Balance sheet, Jun 30, 2026Cash & short-term investments $260.5M · Total debt $599.7M · Total assets $1.41B · Shareholders' equity $504.3M

Dividends

No dividends on record.

Ownership

Institutions 0.76%2.57M sharesInsiders 7.57%25.64M sharesOther 91.67%310.57M shares

Shares outstanding 338.78M · Float 272.81M · 80.5% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Kluge Andreas	22.68M	6.78%	13G	Feb 14, 2025
Christian Behrenbruch · director, officer: MD & Group CEO	21.00M	6.20%	Form 4	May 6, 2026
Mark Alexander Nelson · director	3.63M	1.07%	Form 4	Apr 1, 2026
Jann Elizabeth Skinner · director	595.0K	0.18%	Form 4	Mar 18, 2026
FMR LLC	564.8K	0.17%	13F	May 15, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Apr 28, 2026	Christian Behrenbruch	director, officer: MD & Group CEO	+34,500	$14.48
Apr 29, 2026	Christian Behrenbruch	director, officer: MD & Group CEO	+33,435	$14.87